Logo

HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer

Share this
HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer

HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer

Shots:

  • The P-III (FRESCO-2) trial evaluating fruquintinib + BSC vs PBO + BSC in patients with metastatic CRC who had progressed on standard CT and relevant biologic agents & had progressed on, or were intolerant to TAS-102 & regorafenib at the US, EU, Japan & Australia
  • The trial met its 1EPs of OS & also showed an improvement in PFS. The safety profile was consistent with prior reported studies. The results will be submitted at an upcoming medical meeting
  • The company will discuss the results with the agencies in the US, EU, and Japan & plans to submit fruquintinib’s MAA shortly. The company also retains all commercial rights to fruquintinib outside of China & was marketed under the brand name Elunate

Ref: GlobeNewswire | Image: HUTCHMED

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions